281 related articles for article (PubMed ID: 23451796)
41. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
[TBL] [Abstract][Full Text] [Related]
42. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
43. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
44. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
Heise T; Pieber TR
Diabetes Obes Metab; 2007 Sep; 9(5):648-59. PubMed ID: 17645556
[TBL] [Abstract][Full Text] [Related]
45. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
46. [Insulin degludec--a new basal insulin for the treatment of type 1 and type 2 diabetes].
Gallwitz B; Haak T
MMW Fortschr Med; 2013 Oct; 155 Suppl 3():76-82. PubMed ID: 24930317
[TBL] [Abstract][Full Text] [Related]
47. Insulin degludec (Tresiba)--a new long-acting insulin for diabetes.
Med Lett Drugs Ther; 2015 Dec; 57(1483):163-4. PubMed ID: 26633683
[No Abstract] [Full Text] [Related]
48. Technosphere insulin technology.
Richardson PC; Boss AH
Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S65-72. PubMed ID: 17563306
[TBL] [Abstract][Full Text] [Related]
49. A review of the pharmacological properties of insulin degludec and their clinical relevance.
Haahr H; Heise T
Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
[TBL] [Abstract][Full Text] [Related]
50. Basal weekly insulins: the way of the future!
Rosenstock J; Del Prato S
Metabolism; 2022 Jan; 126():154924. PubMed ID: 34728221
[TBL] [Abstract][Full Text] [Related]
51. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.
Arnolds S; Kuglin B; Kapitza C; Heise T
Int J Clin Pract; 2010 Sep; 64(10):1415-24. PubMed ID: 20618882
[TBL] [Abstract][Full Text] [Related]
52. Degludec: a novel basal insulin.
Kalra S; Baruah MP; Niazi AK
Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
[TBL] [Abstract][Full Text] [Related]
53. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.
Rossetti P; Ampudia-Blasco FJ; Ascaso JF
Diabetes Obes Metab; 2014 Aug; 16(8):695-706. PubMed ID: 24401118
[TBL] [Abstract][Full Text] [Related]
54. [Therapeutic compliance and flexibility in the use of basal insulins].
Costa Gil JE; Litwak LE; Fuente GV; Faingold MC
Medicina (B Aires); 2014; 74(4):273-81. PubMed ID: 25188652
[TBL] [Abstract][Full Text] [Related]
55. Concentrated insulins in current clinical practice.
Schloot NC; Hood RC; Corrigan SM; Panek RL; Heise T
Diabetes Res Clin Pract; 2019 Feb; 148():93-101. PubMed ID: 30583034
[TBL] [Abstract][Full Text] [Related]
56. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
[TBL] [Abstract][Full Text] [Related]
57. Insulin detemir: improving the predictability of glycaemic control.
Russell-Jones D
Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S29-34. PubMed ID: 15306835
[TBL] [Abstract][Full Text] [Related]
58. U300, a novel long-acting insulin formulation.
Sutton G; Minguet J; Ferrero C; Bramlage P
Expert Opin Biol Ther; 2014 Dec; 14(12):1849-60. PubMed ID: 25311556
[TBL] [Abstract][Full Text] [Related]
59. Design of non-standard insulin analogs for the treatment of diabetes mellitus.
Pandyarajan V; Weiss MA
Curr Diab Rep; 2012 Dec; 12(6):697-704. PubMed ID: 22983891
[TBL] [Abstract][Full Text] [Related]
60. Advances in basal insulin therapy: lessons from current evidence.
Singh AK; Sinha B
J Indian Med Assoc; 2013 Nov; 111(11):735-6, 738-42. PubMed ID: 24968481
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
